HIDEHO OKADA
Medical Practice in Pittsburgh, PA

6218180, Apr 17, 2001

Mar 10, 1999

9/267748

Gary J. Kurtzman - Menlo Park CA
Peter C. Colosi - Alameda CA
Jun Yoshida - Nagoya, JP
Masaaki Mizuno - Nagoya, JP
Hideho Okada - Pittsburgh PA

Avigen, Inc. - Alameda CA

C12N 1563, C12N 700, A61K 4800, A61K 3800

4353201

The use of recombinant adeno-associated virus (AAV) virions for the treatment of solid tumors is disclosed. The invention provides for the use of recombinant AAV virions to deliver an AAV vector containing a drug-susceptibility gene and a second gene capable of providing an ancillary effect to solid tumor cells. The second gene can be used to enhance the immunogenicity of the transduced tumor cell. Alternatively, the second gene can be used to provide a tumorstatic effect. The invention also provides for the use of recombinant AAV virions to deliver an interferon gene, or a tumor suppressor gene to provide a therapeutic effect in a transduced tumor cell.

2003022, Dec 4, 2003

Jan 13, 2003

10/342088

Gary Kurtzman - Menlo Park CA, US
Peter Colosi - Alameda CA, US
Jun Yoshida - Nagoya, JP
Masaaki Mizuno - Nagoya, JP
Hideho Okada - Pittsburgh PA, US

A61K048/00, C12N007/00, C12N015/861

424/093210, 514/044000, 435/235100, 435/456000

The use of recombinant adeno-associated virus (AAV) virions for the treatment of solid tumors is disclosed. The invention provides for the use of recombinant AAV virions to deliver an AAV vector containing a drug-susceptibility gene and a second gene capable of providing an ancillary effect to solid tumor cells. The second gene can be used to enhance the immunogenicity of the transduced tumor cell. Alternatively, the second gene can be used to provide a tumorstatic effect. The invention also provides for the use of recombinant AAV virions to deliver an interferon gene, or a tumor suppressor gene to provide a therapeutic effect in a transduced tumor cell.

2010032, Dec 23, 2010

Jun 17, 2010

12/818016

Hideho Okada - Pittsburgh PA, US
Gary Kohanbash - Pittsburgh PA, US
Kotaro Sasaki - Pittsburgh PA, US

A61K 35/12, C12N 5/0783, A61P 35/00

424 9321, 435325

Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype. Thus, the use of Th1-associated miRs for cancer immunotherapy is described. Provided herein are isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR17-92 gene cluster, or a portion thereof. In some embodiments, the T cell is a tumor antigen (TA)-specific T cell, such as a TA-specific CTL. Further provided is a method of treating cancer in a subject by selecting a subject with cancer and administering to the subject an isolated T cell as disclosed herein. Also provided is a method of treating a subject with cancer by transfecting isolated T cells obtained from the subject with a heterologous nucleic acid molecule encoding a Th1-associated miR and administering the transfected T cells to the subject. In some embodiments of the method, the heterologous nucleic acid molecule encodes the miR-17-92 transcript or a portion thereof. In some embodiments, the isolated T cell is a TA-specific T cell, such as a CTL.

5952221, Sep 14, 1999

Mar 5, 1997

8/812102

Gary J. Kurtzman - Menlo Park CA
Peter C. Colosi - Alameda CA
Jun Yoshida - Nagoya, JP
Masaaki Mizuno - Nagoya, JP
Hideho Okada - Pittsburgh PA

Avigen, Inc. - Alameda CA

C12N 1563, C12N 1585, A61K 4800

4353201

The use of recombinant adeno-associated virus (AAV) virions for the treatment of solid tumors is disclosed. The invention provides for the use of recombinant AAV virions to deliver an AAV vector containing a drug-susceptibility gene and a second gene capable of providing an ancillary effect to solid tumor cells. The second gene can be used to enhance the immunogenicity of the transduced tumor cell. Alternatively, the second gene can be used to provide a tumorstatic effect. The invention also provides for the use of recombinant AAV virions to deliver an interferon gene, or a tumor suppressor gene to provide a therapeutic effect in a transduced tumor cell.

2009012, May 14, 2009

Oct 8, 2008

12/247738

J. MARK BRAUGHLER - PITTSBURGH PA, US
PRASANNA KUMAR - COLLEGEVILLE PA, US
WALTER J. STORKUS - GLENSHAW PA, US
HIDEHO OKADA - PITTSBURGH PA, US

A61K 35/12, C12N 15/00, C12N 15/82, C12N 5/08

424 9321, 4353201, 435455, 435366

This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.

2013029, Nov 7, 2013

Jun 24, 2013

13/925093

Hideho Okada - Pittsburgh PA, US

A61K 38/20, A61K 38/17

424 852

Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and/or immunostimulant.

2010000, Jan 14, 2010

Sep 17, 2009

12/561973

Hideho Okada - Pittsburgh PA, US
Walter J. Storkus - Glenshaw PA, US
Junichi Eguchi - Pittsburgh PA, US
Hidemitsu Sato - Ohfuna, JP

University of Pittsburgh - Of the Commonweath System of Higher Education - Pittsburgh PA

A61K 39/00, C07K 7/06, A61K 38/08, A61K 38/10, A61P 37/04

4241851, 530328, 514 15, 514 14

The invention provides a peptide derived from the interleukin-13 receptor α2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use.

2013014, Jun 13, 2013

Jan 9, 2013

13/737316

Walter J. Storkus - Glenshaw PA, US
Hideho Okada - Pittsburgh PA, US

University Of Pittsburgh-Of The Commonwealth System Of Higher Education - Pittsburgh PA
Intrexon Corporation - Blacksburg VA

A61K 35/14

424 9321, 435325, 435455, 435372

This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.